Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Olanzapine in Improving Task Engagement in Schizophrenia.

Next Previous
Trial Profile

Efficacy of Olanzapine in Improving Task Engagement in Schizophrenia.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olanzapine (Primary) ; Antipsychotics
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use

Most Recent Events

  • 26 Dec 2013 Status changed from completed to withdrawn prior to recruitment as per ClinicalTrials.gov record
  • 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 16 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top